Clinical trials
Completed Muscular Dystrophy, Duchenne trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
44 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 2 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 44 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hacettepe University | 6 |
| Cairo University | 2 |
| Nationwide Children's Hospital | 2 |
| University of Florida | 2 |
| University of Sao Paulo | 2 |
| Alan Neuromedical Technologies, LLC | 1 |
| Ankara University | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Children's Hospital of Eastern Ontario | 1 |
| Coordinación de Investigación en Salud, Mexico | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Muscular Dystrophy, Duchenne | 44 |
| Muscular Atrophy, Spinal | 4 |
| Muscular Dystrophies | 4 |
| Neuromuscular Diseases | 4 |
| Amyotrophic Lateral Sclerosis | 2 |
| Cardiomyopathies | 2 |
| Muscular Dystrophy, Facioscapulohumeral | 2 |
| Fibrosis | 1 |
| Gait Disorders, Neurologic | 1 |
| Insulin Resistance | 1 |
Trials
Showing 1 to 25 of 44. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.